Sectors
We work across four related product categories, each with its own evidence base and its own way of going wrong. The evaluation method described on the services page applies throughout, but the specific questions we ask, and the documents we request, differ by category. The table below maps the categories to the evaluation lens that matters most for each; the sections that follow go into the categories individually.
| Category | Representative sub-segments | Primary evaluation lens |
|---|---|---|
| Medical devices | Patient monitoring, surgical instruments, imaging support equipment | Classification, clinical evidence, service life |
| In-vitro diagnostics | Immunoassay, molecular, point-of-care, clinical chemistry | Sensitivity, specificity, reference method comparison |
| Laboratory equipment | Analyzers, centrifuges, incubators, calibration equipment | Serviceability, uptime, spare parts availability |
| Life-science consumables | Reagent kits, culture media, plasticware, reference materials | Lot consistency, shelf life, supply reliability |
Medical devices
Patient monitoring and diagnostic support equipment
Monitoring equipment lives or dies on measurement accuracy and alarm reliability under real clinical conditions, not bench conditions. We look for validation data that reflects the actual patient population and use environment (motion artifact tolerance for pulse oximetry, for example, matters far more in a busy ward than a controlled lab test suggests), along with the device's classification and clearance pathway in its country of origin and whether that pathway maps cleanly to the buyer's own market.
Surgical and procedural instruments
For reusable instruments, reprocessing validation (whether the manufacturer has actually tested and documented that the device withstands its stated number of sterilization cycles without degrading) is one of the most commonly overstated claims in this category, and one of the easiest to check against the manufacturer's own validation report. For single-use instruments, packaging integrity, shelf life, and manufacturing lot traceability carry more weight.
Imaging support and ancillary equipment
Where the core imaging modality is well established, differentiation among manufacturers often comes down to image quality benchmarking against a recognized comparator, software update and support policy, and interoperability with the systems the buyer already runs. We evaluate manufacturer claims about compatibility against actual interface specifications rather than marketing language.
In-vitro diagnostics
Diagnostics are the category where the gap between a headline performance figure and what it actually means is widest, and where getting the evaluation wrong has the most direct clinical consequence. A test with high sensitivity but poor specificity generates false positives that drive unnecessary follow-up testing and patient anxiety; a test with high specificity but weak sensitivity misses cases it should catch. Neither figure means anything on its own, and neither means anything without knowing the reference method the manufacturer compared against and the population the validation study was run in.
Immunoassay and serology platforms
We review cross-reactivity data (what else the assay might be picking up besides its intended target), the reference standard used to establish sensitivity and specificity, and lot-to-lot consistency data across multiple manufacturing batches, not just the batch used in the manufacturer's original validation study.
Molecular and PCR-based diagnostics
Limit of detection claims and turnaround time claims are the two figures most often quoted without full context. We ask for the study conditions behind both, along with the platform's tolerance for the sample types and matrices the buyer will actually be running, which frequently differ from the clean laboratory samples used in a manufacturer's initial validation.
Point-of-care and rapid testing
Point-of-care performance in the hands of non-laboratory operators is frequently lower than performance achieved by trained laboratory staff during a manufacturer's validation study. We look specifically for field or real-world performance data, not just controlled-laboratory validation, and treat the gap between the two as material information for the buyer.
Clinical chemistry and hematology analyzers
Because these platforms typically lock the buyer into the manufacturer's own reagent line, we weigh reagent cost and availability as heavily as instrument performance, and we ask directly about the manufacturer's history of reagent price changes and supply interruptions.
Laboratory equipment and reagents
General laboratory equipment is less often a clinical-evidence question and more often a total cost of ownership question. A centrifuge or incubator that is ten percent cheaper on the purchase order but requires proprietary parts sourced only from the manufacturer's home country, with a six-week lead time for a replacement rotor or sensor, can cost a laboratory far more in downtime than the sticker price ever suggested. We evaluate this category on service life under realistic use, calibration and maintenance requirements, the manufacturer's actual service network (not just its stated one), and whether spare parts and consumables can be sourced regionally or only from the country of manufacture.
Reference materials and calibration standards get particular attention on traceability: whether the material is traceable to a recognized international reference standard, and whether the manufacturer can produce the certificate of analysis for the specific lot being supplied, not a generic specification sheet.
Life-science consumables
Consumables, reagent kits, culture media, pipette tips, general plasticware, and similar items rarely fail on performance alone; they fail on consistency and continuity of supply. A reagent kit that performs perfectly in a validation study but is reformulated or discontinued eighteen months later, with no equivalent replacement, creates real disruption for a laboratory that has built a workflow around it. We evaluate manufacturers in this category on lot-to-lot consistency data, documented shelf-life and storage stability, and, where the buyer's volumes justify it, evidence of production capacity sufficient to support ongoing rather than one-time supply.
What we do not cover
We do not evaluate pharmaceuticals, biologics, or products that fall under a drug regulatory pathway rather than a device or diagnostic pathway; that is a different evidentiary framework and a different regulatory system, and we do not represent expertise there. We also do not arrange shipping, customs clearance, or in-market distribution for any product we evaluate, and we do not hold inventory or take title to goods at any point. If a category you are working in does not fit clearly into medical devices, in-vitro diagnostics, laboratory equipment, or life-science consumables, get in touch and describe it; we will tell you directly whether it is a fit.